This Current Report on Form 8-K (this “Report”) is being filed in connection with the completion of the transactions contemplated by the previously announced Membership Interest Purchase Agreement, dated as of April 21, 2026 (as it may be amended from time to time, the “Purchase Agreement”), by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal”), Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”). On August 10, 2026 (the “Closing Date”), pursuant to the Purchase Agreement, Amneal Pharmaceuticals LLC, a Delaware limited liability company and wholly owned subsidiary of Amneal (“Amneal LLC”), acting pursuant to the terms and conditions of a previously executed assignment and assumption agreement between it, Amneal, Kashiv and the Seller Representative, purchased from the Sellers, and the Sellers sold, conveyed, assigned, transferred and delivered to Amneal LLC, 100% of the issued and outstanding membership interests of Kashiv (the “Acquisition”). Pursuant to the Purchase Agreement, at the closing of the Acquisition (the “Closing”), (i) Amneal LLC was required to pay to the Sellers $375,000,000 in cash, subject to certain purchase price adjustments including for cash, the funding of operations between signing and closing (subject to a specified cap, calculated on the basis of the period from the date of the Purchase Agreement until the Closing), indebtedness, transaction expenses and working capital fluctuations (relative to a target), and (ii) Amneal was required to issue to the Sellers 28,942,108 shares of its Class A common stock, par value $0.01 per share, subject to adjustments for fractional shares. The Sellers will also be eligible to receive up to an additional $350,000,000 in potential contingent payments upon the achievement of certain regulatory milestones in the United States for up to six designated Kashiv product candidates. In addition, during the 12-year period following the Closing, the Sellers will be eligible to receive certain potential contingent royalty payments equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty period.

As previously reported, certain of the Sellers are affiliates of the Amneal Group (as defined in Amneal’s proxy statement for its 2026 annual meeting of stockholders, which was filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2026).

The foregoing description of the New Incremental Term Loan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the New Incremental Term Loan Amendment, which is attached hereto as Exhibit 10.2.

The information set forth in the Introductory Note of this Report is incorporated into this Item 2.01 by reference.

The information set forth in the Introductory Note and Item 1.01 of this Report is incorporated into this Item 2.03 by reference.

The information set forth in the Introductory Note of this Report is incorporated into this Item 3.02 by reference. Pursuant to the Purchase Agreement, upon the Closing, Amneal issued to the Sellers 28,942,098 shares of its Class A Common Stock, par value $0.01 per share (as adjusted downward for fractional shares pursuant to the Purchase Agreement, the “Stock Consideration”). The issuance of the Stock Consideration to the Sellers was made in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof as a transaction by an issuer not involving any public offering. The Sellers represented to Amneal that they are “accredited investors” as defined in Rule 501 of the Securities Act and that the securities are being acquired for investment purposes and not with a view to, or for sale in connection with, any distribution thereof. Pursuant to the Purchase Agreement, Amneal has agreed to file with the SEC a registration statement on Form S-3 to provide for the public resale of the Stock Consideration by the later of (i) 30 days following the Closing Date and (ii) 10 business days following the receipt by Amneal of information reasonably required from the Sellers to be included or incorporated by reference in such registration statement.

On the Closing Date, Amneal issued a press release announcing the closing of the Acquisition. A copy of the press release is attached as Exhibit 99.1 hereto.